no can do, sorry. if there were a transcript i could pull it off but i can't hear the words clearly enough.
luckily the researchers' english is far better than my french:
http://www.geneuro.com/index2.php?rubID=25
GeNeuro develops therapeutic monoclonal antibodies to neutralize the immunopathogenic MSRV/HERV-W envelope proteins detected in MS brain plaques by independent studies, thus blocking the inflammatory cascade at the origin of brain lesions.
GeNeuro is developing humanized antibodies with external partners using state of the art technology. Those new antibodies will be soon evaluated with two animal models reproducing the MSRV/HERV-W envelope protein pathology developed with external collaborations before entering clinical trials within the next 2 years. The lead compound, GENHP-01 is in MS.
Following repeated transversal successful studies that validated the pathogenic MSRV/HERV-W envelope protein target in MS patients, a parallel longitudinal study is conducted on MS patients and will be completed before starting the clinical trials.
In addition, we are investigating the human endogenous retrovirus approach in the field of schizophrenia and other neurological diseases. Patients’ recruitment has already started.